Bullfrog AI (BFRG) investor relations material

Industry challenge

• Drug development typically takes 10–15 years and costs $1 billion–$2 billion; phase III programs fail 50% of the time.

Platform and capabilities

• Proprietary platform originated at Johns Hopkins Applied Physics Lab; bfPREP prepares complex biomedical data, bfLEAP analyzes it, and bfARENAS supports decisions on targets and biomarkers.

• bfPREP can clean, harmonize, and structure large datasets in hours or days; one top-five pharma reported 100,000 datasets needing preparation.

• Exclusive access to the Lieber Institute for Brain Development’s neuropsychiatric brain dataset supports work on major depressive disorder, bipolar disorder, and schizophrenia.

Commercial progress

• March deal with a top-five pharma followed a year of selling and diligence; the work identifies major depressive disorder targets, with the pharma partner expected to select one for in-house development.

• Performance on the project has prompted interest in expansion across four to six areas; potential opportunities were described as multimillion-dollar, potentially tens of millions.

• Pipeline has about three dozen opportunities; a commercial team was recently hired, with one or two additional deals seen as possible in the quarter and sales cycles reportedly shrinking.

• Eleison Pharmaceuticals’ pancreatic cancer phase III analysis identified a patient subgroup and biomarkers associated with a 3X survival improvement.